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The effects of irr&ravenous magnesium on exercise-induced 
angina were examined in I5 patients wi% variant szgka 
and in 13 p&ients with stable effort angina and were 
compared with those of placebo. Symptom-limited bicycle 
exercise and thallium-201 myocardial xintigraphy were 
performed after intravenous administration of 0.27 mm& 
kg body weight nf -iurn sulfate and after ptaceba on 
diRerent days. In all patients, serum magnesium levels after 
administration of magnesium sulfab were about twofold 
lighcr than kvek after placebo. 
Exercise+&ced angina asseciated with transient ST 
segment elevation occurred in 11 patknls with variant 
angina receiving placebo and in only 2 of these patients 
receiving mngacsiur (p<O.OO!$ On the o!her hand, exer- 
cise-iiuced angina was nut ssppressed iiy magnesium in 
any patiint with stable eKort angina. In these patients there 
was no significant difference in exercise duration after 
administration of placebo versus after ad!ninistralion of 
magnesium. The size uf the perfusiun defect 8~ measured by 
thallium-201 scintippby was signitkantly lejs in patients 
with variant angina receiving magnesium thnn that in those 
receiving placebo ~p<O.oOl), whereas it was nut signifi- 
cantly different in patients with stabk effort angina receiv- 
ing placebo versus magnesium. 
In sonelusion, exercise-i&cod angina is suppressed by 
intravenous magnesium in patients with variant angina but 
not in patients with stabte etfoft angina. I.rls ben&cial 
e&:1 of magnesium in patients with variant angina is most 
likely due to ilaprovement of regional myocardial b&d 
flow by suppressiun of coronary artery spasm. 
(J Am Cdl Cardial 1988;12:3177-8~) 
Angina pectoris is a clinical syndrome caused by transient 
myocardial ischemia due to .m imbalance between myocar- 
dial oxygen demand and supply, and classical stable effort 
angina has been explained on the basis of increased myocar- 
dial oxygen demand in the presence of a fixed coronary 
stenosis (I ,2). However, short-term reduction of regional 
myocardial blood flow due to coronary artery spasm has now 
been accepted as the pathngenetic mechanism for attacks 
occurring at rest or during exercise in patients with variant 
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angina (3-l 1). We and other investigators (612) have shown 
that the drug of choice for treatment of patients with variant 
angina is a calcium channel antagonist, which suppresses 
coronary spasm, rather than a beta-adrenergic blocking 
agent, which decreases myocardial oxygen demand. 
Magnesium is one of the most plentiful and important 
intracellular cations in !he body. Previous reports (13.14) 
Gxxcd :!ia: pa:cntcrai use of magi&urn bulLale relieves 
angina1 symptoms and improves exercise capaci!:l in pa- 
tients with exertional angina. However. these reports were 
based on noncontrolled clinical trials, and the mechanism 
explaining their results remained unclear. Recently (151, WC 
demonstrated an increased retention rate of loaded magne- 
sium in patients with variant angina or coronary spasm. 
suggesting that magnesium d&kiency may be involved in the 
pathogenesis of coronary spasm. Other animal studies (16 
19) also support this suggestion on the basis of in vitro 
experimental findings that magnesium plays a regulatory role 
in coronary vascular tone by its influence on calcium ion 
uptake, content and distribution in vascular smooth muscle. 
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In this context. some studies (20.21) propose that magne- Table 1. Clinical Characteristics of IS Patients With 
sium is nature’s physiologic calcium anlagonisl. However. Variant Angina 
there is no systematic and controlled study concerning the 
effects of mugncsium on angina caused by coronary spasm in 
ST Elevation 
Coronary Arteriography 
Faticnt Age (yr) & During After 
patients with variant angina. No. Gender Spontaneous Attack Attack W NTG 
We have shown (6-11) that exercise-induced coronary 
spasm occurs frequently and is a cause of exertional angina 
1 67M II. Ill, aVF 99 s2* Normal 
with ST segment elevation or depression. or both, in the 
2 6RM IL III. aVF 99 s2 Normat 
3 S6M V, toV, 99 Sh Normal 
early morning in many patienls with variant angina. Exercise 4 6IM IL Ill. aVF, IQ0 Sh Normal 
thalIium-201 myocardial scintigraphy provides quantitative and V, lo Vq 99 s3 
information concerning myocardial blood flow to the ische- 5 46M I. aVL. v, to v, Ion s5 Normal 
mic areas (22.23). Our previous studies (7.8) demonstrated 6 49F Ill. aVF 90 54 Normal 
that the technique of combining exercise in the early morn- 7 71M I. aVL. Vd IO v, 99 SII Normal 
ing with thallium-201 myocardiai scintigraphy in patients 
8 58M II. III. aVF IQ0 SI Normal 
with va;iant angina is useful for the noninvasive evaluation 
9 68M v, toV, 100 S6 Normal 
10 72M II. III. aVF loo SI Normal 
of the effects of antianginal drugs on attacks caused by tt 49M v, tov3 99 S6 90% S6 
coronary spasm. In this study, using quantitative rotational I? 4SM II. Ill. aVF Km S! 75% $6 
thallium-201 tomography. we examined the effects of intra- 13 60M II. III. aVF loo s2 75% s2 
venous magnesium sulfate on exercise-induced angina in 14 S7M II. III. aVF loo 54 90% s4 
different types of patients with angina pectoris. I5 49M V, tov, loo .%I 90% SI 
90% S6 
Methods 
Study patients. The study population consisted of two 
different groups of patients with exercise-induced angina. 
Group I consisted of 15 patients with variant angina (14 men 
and I woman, aged 45 IO 72 years [mean 581); Group two 
included I3 patients with stable effort angina (12 men and I 
woman, aged 44 to 68 years, mean 1571). Group I patients 
with variant angina fulfilled the following inclusion criteria: 
I ) .TI)~~II~I~~II.~ rr~trrc.lrs of CIIPSI p&r rrs.wwinted IIVWI ST 
.wg:nr~w~ ckrwhxz PO.2 mV above the control level) on the 
electrocardiogram (ECG! at rest. usually in the middle of the 
night or early morning. and more than two times a day during 
the sludy. 2) Rcprohri~h csclri.\r-in(llrl.rd rrrtgirtd ultarks 
associated with ischemic ST segment deviations during 
rcpcated treadmill or ergometer tests. or both. in the early 
morning during the study. ST segment deviations during 
exercise-induced angina appeared in the same ECG leads in 
which ST segment elevation was observed during the spon- 
taneous attack. 3) Coroonrrr~ spcrsn demonstrated arterio- 
graphicahy during the angina) altack in a large coronary 
artery perfusing! the left ventricular area corresponding IO 
the sirp of ST segment elevation during the spontaneous 
at&i.: A sumtiary of the cliriicai data in patients with 
variant angina i* shown in Table I. 
Group 2 stul; y patients with stable effort angina had an 
exercise-induced fixed-threshold angina1 attack with hori- 
zontal or downsloping ST segment depression (>O.l mV 
below the control level), but none had rest or nocturnal 
angina. ST segment elevation or other clinical findings 
suggesting coronary spasm. On arteriography. all Group 2 
patients had ~70% luminai diameter narrowing in at least 
*SI IO SIS indicale segments of the coronary arteries showing spasm. as 
defined by the American &art Association Committee Report (241. F = 
female: M = male: NTG = nitroglycerin, 
one major coronary artery (four patients in one artery, five in 
two arteries and four in three arteries). 
No patient in either group had prior myocardiai infarc- 
tion, heart failure, impaired renal function or other severe 
complications. All patients in both groups had normal serum 
levels of magnesium, potassium and calcium at the time of 
entry into the study. The two groups of patients did not 
significantly differ with respect to age, gender and serum 
electrolyte levels. Ail patients gave informed consent before 
they were included in this study. 
Study protoco!. This study was performed by a singie- 
blind placebo-controlled protocol. In all paiients the study 
was performed in the early morning because exertional 
angina occurs most frequently during the first exercise in the 
morning in patients with variant angina (4-i I), A!! medica- 
tions were discontinued z-10 days before the study except 
for nitroglycerin, which was stopped 2 h before the study. In 
all patients, 0.27 mmollkg body weight of magnesium sulhte 
(dissolved ir. 100 ml of isotonic glucose) and placebo (100 ml 
of isotonic glucose) was administered intravenously ovec a 
period of 20 min early in the morning on the day of infusion. 
Blood pressure. heart rate and deep tendon reflexes were 
monitored immediately before and during each infusion. 
This infusion rate of magnesium sulfate was chosen to cause 
about a twofold transient elevation of the serum magnesium 
level at which ievzl serious toxic effects due to hypermagne- 
semia are unlikely to appear (25). Each infusion of placebo 
or magnesium was performed singly on separate early morn- 
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ings with an intervening interval of 1 week. The sequence of 
each tnal was randomized. 
Exercise and thallium xintigraphic procedure. Using the 
same methods as described in our previous studies {7,8). 
each patient performed the exercise and thallium-201 myo- 
cardial scintigraphic tests 30 min after completion of each 
infusion of magnesium sulfate or placebo. The exercise test 
was performed with the patient in the upright position on an 
electrically graded bicycle ergometer (380B. Siemens-Elema 
AB) starting at a work load of 50 W with increments of 25 W 
every 3 min. A 12 lead electrocardiogram (ECG) and blood 
pressure (measured by the cuff method) were recorded at 
rest, during exercise and several minutes after exercise. All 
patients had undergone the same ergometer test at least 
twice before the study so that they became familiar with the 
test procedure. A bolus of 2.5 mCi of thallium-201 was 
injected through an indwelling intravenous infusion line at 
the time when anginal chest pain or exhaustion appeared. 
The patient was encouraged to continue the exercise at the 
same fevel for 30 s after the injection of thallium-201. 
lmaging began 5 min after the injection of thallium-201 with 
use of the same system of single photon emission computed 
tomography and dedicated computer (ZLC137-ECT and 
Scintipack 2400, Shimadzu Inc.) described in our previous 
studies (7,8). The short-axis tomographic images encom- 
passing the entire left ventricle were reconstructed ai 6.0 mm 
intervals. 
Quantitative analysis of defect size on the scintigram. The 
computerized thallium-201 tomographic method proposed 
by Garcia et al. (26) and Ritchie et al. (27) was used to 
quantify the size of the perfusion defect. This approach was 
also used in our previous studies (7, 8). In brief, circumfer- 
ential profiles for each short-axis tomographic image were 
constructed from maximal count values per pixel in each of 
60 radii spaced at 6” intervals. Count vs!ues on each point in 
the profile were then normalized to the maximal count in the 
profile of each image. The resulting profiles were arranged as 
a series of concentric circles forming a single two- 
dimensional polar map. Then, extent and severity polar 
maps were obtained by comparing normalized maximal 
count values per each point on the generated two- 
dimensional polar map with the corresponding lower normal 
limits at 2.5 standard deviations below the mean derived 
from 30 normal subjects. The extent polar map represents 
extent of count reduction and !hn E.*‘* .._ ,,.eriiy map represents its 
sev=;ity 
Tile erlent score fur the size of Ihr perfzzsion defect M’NS 
rlrfn~d by calculating the number of points falting below the 
corresponding lower normal limits and by expressing this 
number as a percent of the total left ventricular points on the 
extent polar map. The severity score was determined by 
calculating the difference between normalized maximal 
counts per each point in the area of the defect and corre- 
sponding lower normal limits and by dividing this difference 
by the total number of left ventricular points on the severity 
map. 
Magnesium and other electrolytes assay. After the infu- 
sions of magnesium sulfate and placebo, blood samples were 
obtained immediately before the exercise test. Serum mag- 
nesium concentration was determined by atomic absorption 
spectrophotometry (Perkin-Elmer Inc.). Serum calcium and 
potszclum concentrations .vere determined with a Technicon 
SMAC-I autoanalyzer. 
Statistical analysis. Fisher’s exact test was used to com- 
pare the incidence of angina and ST segmen! e!ev.&a 
during the exercise test after magnesium infusion with that 
after placebo. The serum electrolyte values, hemodynamic 
variables and scintigraphic defect size were expressed as 
mean valuek 2 SD and were stadsiically analyzed by use of 
Student’s phired t test. 
Results 
iutravenaus administration of magnesium sulfate and pta- 
cebo (Table 2). In all patients. serum magnesium levels 
immediately before the exercise test after magnesium sulfate 
infusion were significantly higher (about twofold) than after 
placebo. There was no significaut difference in heart rate (67 
2 I2 ‘Jersus 70 f 12 beatslmin, p = YS) and in systolic blood 
pr:s:,lre (I30 2 24 versus 12R 5 23 mm Wg. p = NS) 
between before and at the end of the infusion of magnesium 
sulfa!e, respectively. Slight cutanecns flushing occurred in 
all patients during the infusion of magne:;ium su!fate, which 
promptly disappeured 55 min after termination of the infu- 
sion. Toxic effects due to hypermagnesernia, such as depres- 
sion of respiratory rate and of deep tend& reflexes, were not 
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Table 3. Exercise Variables After Each Infusion of Placebo and Magnesium sulfate in Both 
Patient Grouts 
Ex duration 
Rest HR 
Rest SBP 
Peak HR 
Peak SBP 
Peak RPP 
Variant Angina (n = 15) Stable Effort Angina (n = 13) 
Placebo Magnesium p Value Placebo Magnesium p Value 
3.5 2 2.0 7.3 * 2.1 <o.aor 5.4 2 2.9 5.0 f 1.7 NS 
672 IO 672 IS NS 75 f I3 702 13 NS 
127 + 26 124 2 25 NS 126 f 23 130 Lt 21 NS 
103 r 20 121 = 19 <O.Ol 120 + 20 114 f 19 NS 
148 + 31 173 + 32 <o.os 164 f 26 171 * 23 NS 
IS.521 + 5, I65 20.995 2 5.204 co.01 20.019 f 6.032 19.700 f 4.715 NS -_- 
Values are mean + SD. Statistical analysis was performed by use of a Student’s paired I fest. Ex duration = 
exercise duration (min); HR = hear! rate (beatslmin); RPP = rate-pressure product (mm HgbeaWmin); SBP = 
systolic blood pressure (mm Hg). 
observed in any patient during the infusion of magnesium 
sulfate. Serum calcium and potassium levels after the admin- 
istration of magnesium sulfate did not change significantly as 
compared with levels after the administratioti of placebo. 
Exercise results in patients with vartant angina (Table 3 
and Fig. I to 3). An attack of chest pain was induced during 
exercise after placebo infusion in ail 15 Group i patients with 
variant angina, whereas it was induced in only 5 patients 
after magnesium (p -C 0.001). ST segment elevation occurred 
transiently after placebo adminisiration during the exercise- 
induced attack of chest pain in II of the 15 patients with 
variant angina whereas it occurred in 2 patients after mag- 
nesium (p < 0.005) (Fig. I). The exercise duration in patients 
with variant angina was longer after magnesium than that 
after placebo (p < 0.001). Immediately before exercise, the 
baseline values of heart rate and systolic blood pressure after 
magnesium infusion were not significandy different from 
those after placebo infusion. However, at peak exercise, 
Figure 1. Case II. Top, Electrocardiogram during the ergometer 
exercise test in a patient with variant angina whose thailium +cinti- 
grams are shown in Figure 3. Bottom, exercise-induced angina with 
ST segment elevation was suppressed after intravenous adminislra- 
tion of magnesium (Mg), BP = blood pressure. 
REST EXERCISE 
PLACEBO 
both the heart rate and systolic blood pressure were signif- 
icantly higher after magnesium than those after placebo 
(heart rate, p < 0.01; systolic blood pressure, p c 0.05). 
Therefore, the peak rate-pressure product was also signifi- 
cantly greater after magnesium than after placebo {p < 0.01). 
indicating that myocardial oxygen demand at peak exercise 
was significantly increased by magnesium infusion. 
Each patient had a perfisjon defect in the scinrigraphic 
area believed to be perfirsed by the coronary artery in which 
spasm was arteriographically demonstrated. The extent and 
severity scores of the scintigraphic perfusion defect were 
significantly less after magnesium than after placebo (extetit 
score: 12.7 f 16.9 versus 40.4 f 16.%, p < 0.001; severity 
score: 0.98 f 1.72 versus 4.49 2 2.59 normalized counts/ 
point, p < 0.001) (Fig. 2). In all patients with variant angina, 
the size of the perfusion defect markedly decreased after 
magnesium ad compared with that after placebo. However, 
Figure 2. Effects of magnesium (Mg) on the extent (Mk) and severity 
(right! scores of defect size on the thallium scintigrams in 15 patients 
wub variant angina compared with those of placebo. Open circks 
with horizontal bar indicate mean values. The asterisk indicates five 
patients with fixed coronary stenosis. 
100 r W- 
p<o.o01 peo.001 
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Figure 3. Case I I. Polar representations of myocardial 
dish-ibution of thallium-201 dunng the ergometer exer- 
cise tests in the patient with vanant angina whose 
efectrocardiogwm during the exercise tests is shown in 
Figure I. Two-dimensional polar maps !kfi) represent 
three-dimensional myocardial count distribution on a 
scale ranging from white (high counts) IO black (low 
counts). The extent polar maps (center) represent a 
binary map on which points falling below the corre- 
sponding lower normal limits are shown as a black 
region and the remaining points fall in a whitz region. 
The severity polar maps (right) indicate the grade of 
count reduction at each point on a scale ranging from 
light gray (low grade) to black (high gqde) in the 
magnitude of count reduction below lower normal lim- 
its. In these polar map representations, activity from the 
apex of the left ventricle is located at the center. that of 
the base at the periphery, inferior waH at the bottom. 
septum on the left, and lateral wall on the right. The 
perfusion defect in the anteroseptal area aRer exercise 
for those receiving a placebo markedly decreased when 
administered magnesium. 
scintigrams after the administration of magnesium. SW 
imp&ement with magnesium is most likely due to suppres- 
sion of exercise-induced coronary spasm because the num- 
ber of patients showing exercise-induced angina with ST 
segment elevation-which indicates severe reduction of re- 
&al myocardiat blood tlow probably due to coronary 
spasm (28+29Mecreased significantly after the a$ministra- 
tion of magnesium. 
In contrast to the favorable results in patients with variant 
angina, magnesium did not lessen exercise-induced angina in 
patients with stable effort angina. This lack of effect may be 
hue to the failure of magnesium to reduce myocardial oxygen 
demand, as indirectly demonstrated by the peak rate- 
pressure product. Moreover. magnesium did n& improve 
myocardial blood flov: to ischemlc areas, as shown by the 
scintigraphic study. 
Mechanism d AlsgReJiam e&Is 011 coronary spasm. Epi- 
demiologic studies (30-32) suggest that ischemic heart dis- 
Discussion 
Effect of magnesium on exerci&nduced angina and 
spasm. This study shows that intravenous magnesium sul- 
fate suppresses the exercise-induced angina in patients wrth 
variant angina. All patients with variant angina performed 
exercise for a longer period and to a greater work load when 
receiving magnesium than while receiving placebo, and the 
peak rate-pressure product, an indirect index of myocardial 
oxygen demand, increased after magnesium infusion as 
compared with that after placebo- These beneficial effects in 
patients with variant angina seem to be due to improvement 
of myocardial blood flow to ischemic areas. as demonstrated 
by the decreased Gte of perfusion defects on the thallium 
Figure 4. Effects of magnesium (Mg) on the extent Oeftl and severily 
hi@) scores of thallium defect size on the scintigrams in 13 oatients 
with stable etlbrt angina compared with those after placebo. Open 
circles with horizoaltt4 bar indicate mean values. 
6r 
O- o- 
I I I I 
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ease may be related to magnesium intake because the 
incidence of the disease has been shown to be high in areas 
with a low concentration of magnesium in drinking water. 
Furthermore, we have previously observed (15) magnesium 
deficiency in patients with variant angina. This observation 
and other reports (16,21,33) suggest that magnesium defi- 
ciency may be involved in the pathogenesis of coronary 
spasm, which has an important role in the many clinical 
conditions related to ischemic heart disease (3-l I). This line 
of thinking was supported by the in vitro experimental 
findings of Turlapaty and Altura (16) that a low extracellular 
magnesium concentration increased the basal tone of an 
isolated canine coronary artery and potentiated its contrac- 
tile responses to circulating vasoconstrictor hormones such 
as norepinephrine. On the other hand. a high magnesium 
concentration decreased the basal tone of the coronary 
artery and depressed its reactivity to contractile agonists. 
Altura, Turlapaty and other authors (17-W) further showed 
in vitro evidence that magnesium physiologically competes 
with calcium, which is essential for regulation of the tone 
and contraction of vascular smooth muscle at the membrane 
and at intracellular calcium-binding sites in vascular smooth 
muscle including the coronary artery, In this sense, magne- 
sium appears to be a natural calcium antagonist (20). Thus, 
this study in patients with variant angina supports the 
probability (16-21) that a high magnesium level can inhibit 
the contraction of coronary vascular smooth muscle. 
Conclusions. It is now widely accepted that coronary 
spasm plays an important role in the pathogenesis not only of 
variant angina but also of other forms of angina ai rest, 
unstable angina and acute myocardial infarction (3-l I). This 
stody suggests the possibility that intravenous magnesium 
may have value as a treatment of these types of ischemic 
heart disease. 
We are grateful to Mario S. Verani, MD (Baylor College of Medicine, 
Houston, Texas) for critical review of the manuscript and to Maria E. Frias 
for expert secretarial assistaxe in its preparation. 
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